ClinicalTrials.gov
public full text
Public Domain
Rifampicin at High Dose for Difficult-to-Treat Tuberculosis
The purpose of this study is to assess the safety of rifampicin given at a dose three times as the standard one, in persons with tuberculosis that belong to groups that have not been widely included in previous trials.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment#839164
- Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide#834478
- Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis#844972
- Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis#261313
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis#1095481
Record · ID 898292
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive